CN115736319A - 荷荷巴油在制备电子烟烟液中的应用 - Google Patents
荷荷巴油在制备电子烟烟液中的应用 Download PDFInfo
- Publication number
- CN115736319A CN115736319A CN202211232830.8A CN202211232830A CN115736319A CN 115736319 A CN115736319 A CN 115736319A CN 202211232830 A CN202211232830 A CN 202211232830A CN 115736319 A CN115736319 A CN 115736319A
- Authority
- CN
- China
- Prior art keywords
- parts
- jojoba oil
- cigarette liquid
- electronic cigarette
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940119170 jojoba wax Drugs 0.000 title claims abstract description 106
- 239000003571 electronic cigarette Substances 0.000 title claims abstract description 100
- 239000007788 liquid Substances 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 96
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000002904 solvent Substances 0.000 claims abstract description 39
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 35
- 229960002715 nicotine Drugs 0.000 claims abstract description 35
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 3
- 230000008569 process Effects 0.000 claims abstract description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 68
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 52
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims description 44
- 235000001510 limonene Nutrition 0.000 claims description 34
- 229940087305 limonene Drugs 0.000 claims description 34
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 26
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 26
- 229930007744 linalool Natural products 0.000 claims description 26
- 229940073505 ethyl vanillin Drugs 0.000 claims description 22
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 claims description 16
- 241000208125 Nicotiana Species 0.000 claims description 14
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 14
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 claims description 14
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 abstract description 29
- 210000004072 lung Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 3
- 210000000621 bronchi Anatomy 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 229960004063 propylene glycol Drugs 0.000 description 33
- 235000013772 propylene glycol Nutrition 0.000 description 32
- 239000000796 flavoring agent Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000779 smoke Substances 0.000 description 9
- 206010069351 acute lung injury Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000007908 nanoemulsion Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 235000010389 delta-tocopherol Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 150000003785 γ-tocopherols Chemical class 0.000 description 3
- 150000003789 δ-tocopherols Chemical class 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 125000001020 α-tocopherol group Chemical group 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000015219 food category Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- OSELKOCHBMDKEJ-WGMIZEQOSA-N isofucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC/C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-WGMIZEQOSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/26—Use of organic solvents for extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种荷荷巴油在制备电子烟烟液中的应用,即在制备电子烟烟液的过程中,将荷荷巴油作为溶剂使用。本发明的有益之处在于,用于取代或减少丙二醇和甘油作为电子烟烟液的溶剂的荷荷巴油,没有毒性,具有运载与雾化尼古丁的功能,又能对肺部、支气管和气管细胞有很好的保护作用,对皮肤没有刺激作用,对酸败表现出很高的抵抗力。
Description
技术领域
本发明属于电子烟烟液制备技术领域,特别涉及一种荷荷巴油在制备电子烟烟液的应用。
背景技术
电子香烟,即电子尼古丁输送系统ENDS,目前在国内外迅速普及。由于电子烟不涉及烟草燃烧,尼古丁(烟碱)和其他成分在吸入前被雾化,与传统卷烟相比,虽然不燃烧可以减少电子烟使用者的有毒物质暴露,但使用者和非使用者还是会接触到含有电子烟烟液成分的气溶胶。
电子烟烟液,或称电子烟烟油,其中最大成分是溶剂,有时也称为保湿剂或稳定剂。电子烟烟液配方中,溶剂的目的是使其他化学成分如烟碱和调味剂保持悬浮状态,增强设备中芯吸材料的吸收,并产生雾化的烟气羽流。目前,电子烟烟液所用的两种最常见的溶剂是丙二醇和甘油(丙三醇)。美国FDA在关于食品和人类消费的B分章将丙二醇归类为“公认安全”(GRAS),可用于摄入,但不能用于雾化。它定义了消费品的最高含量,例如冷冻乳制品中的2.5%,调味料和调味料中的最高97%,以及所有其他食品类别中的2%。甘油在同一子章节中也被归类为“公认安全”,但未定义最高水平。相反,当按照良好生产规范使用时,该物质是公认安全。丙二醇和甘油在电子烟烟液中可以不同的比例存在,一般占电子烟烟液体积的80%~95%。丙二醇和甘油是分别具有两个和三个醇基团的三碳化合物。与丙二醇相比,甘油上的额外醇基有助于提高沸点、粘度、气溶胶密度和较低的蒸气压。许多电子烟商家并没有通过这些措施进行比较,而是根据与消费者相关的标准来比较丙二醇和甘油,例如喉咙感觉、残留物积聚和风味强度。甘油会增加电子烟烟液的味道并产生大量的气溶胶,这些溶剂通常以混合物形式存在于电子烟烟液配方中,常见的丙二醇:甘油比为10:90、20:80、50:50和80:20,尽管市场上存在许多其他比率。
丙二醇与甘油的比例会影响电子烟体验的许多方面,例如尼古丁产量、烟液消耗量和有毒热分解产物的产生。丙二醇和甘油都是气道刺激物,雾化丙二醇和甘油会引起口腔和咽喉刺激和干咳,高功率的丙二醇/甘油气雾剂的急性吸入会导致年轻吸烟者的气道上皮损伤和经皮氧张力持续下降。甘油可以增加吸入剂的功效,它具有吸湿性,可将水吸入支气管分泌物并降低其粘度。有报道当人类胚胎干细胞、小鼠神经干细胞和人类肺成纤维细胞暴露于几种电子烟补充溶液时,甘油和丙二醇不会引起细胞毒性作用。然而,与电子烟使用相关的反复且可能长期吸入甘油蒸气的情况与细胞水平的暴露不同,目前可用的数据不足以确定长期安全性。--【PriscillaCallahan-Lyon,Electroniccigarettes:humanhealtheffects,TobControl.2014May;23(Suppl2):1136–1140】。据报道,丙二醇和甘油在加热时都会形成有毒的醛类。丙二醇还会引起眼睛、喉咙、粘膜和呼吸道刺激和外周气道收缩,人体急性吸入暴露于雾化丙二醇会导致喉咙不适、咳嗽和1秒用力呼气量/用力肺活量(FEV1)减少。有关实验表明,暴露于丙二醇气溶胶仅2小时的兔子显示出气管杯状细胞退化的证据。尽管大鼠对短暂暴露于雾化丙二醇有相对抵抗力,但长期暴露已被证明会增加鼻杯状细胞数量和粘蛋白含量,刺激鼻和眼粘膜,并引起喉鳞状上皮化生。--【aurenF.Pulmonarytoxicityofe-cigarettes.AmJPhysiolLungCellMolPhysiol.2017Aug1;313(2):L193–L206.】。有研究观察电子烟液主要成分的1,2-丙二醇对斑马鱼早期发育的影响。通过把斑马鱼胚胎在受精后6至72小时暴露于1.25%或2.5%1,2-丙二醇中。实验观察表明暴露于1,2-丙二醇不会显着影响死亡率。在48小时,2.5%1,2-丙二醇暴露的胚胎的孵化成功率显著降低,但在72小时未发现显着差异。此外,暴露于1,2-丙二醇会降低生长并增加心绞痛、心包水肿和卵黄囊水肿的发生率。最重要的是,斑马鱼的发育暴露于1.25%1,2-丙二醇会导致幼虫过度活跃的游泳行为。这项研究表明,1,2-丙二醇对斑马鱼的早期发育有不利影响。--【Massarsky,A.Exposureto1,2-Propanediolimpactsearlydevelopmentof Zebrafifish(Daniorerio)andinduceshyperactivity.Zebrafifish(2017).14,216-222】。
由于电子烟烟液的最大成分是溶剂丙二醇和甘油,而丙二醇和甘油存在以上的缺陷,长期应用可能对使用者造成不利的影响。
荷荷巴油(Jojobaoil),提取自一种广泛使用的药用植物,该药用植物在世界范围内均有种植。荷荷巴油由几乎98%的纯蜡(主要是蜡酯,少量游离脂肪酸、醇类和碳氢化合物)、甾醇和维生素组成。甾醇部分的主要成分是胆固醇、β-谷甾醇、菜油甾醇、豆甾醇和异褐藻甾醇。脂溶性维生素主要是维生素D及其衍生物,α、γ和δ生育酚,其中γ-生育酚约占这些化合物的79%。还发现了其他脂溶性维生素,例如维生素A等,几乎没有甘油三酯,因此它被广泛称为液体蜡而不是油或脂肪。通过冷压或溶剂提取种子直接获得的粗荷荷巴油,未经任何修饰,可产生金黄色或浅黄色油。它有一种令人愉快的、略带坚果味的味道。荷荷巴油的热稳定性和氧化稳定性高;因此,由于存在天然抗氧化剂(α、γ和δ生育酚),该油对酸败表现出很高的抵抗力。荷荷巴油在民间传说中有着悠久的历史,用于治疗各种疾病,如皮肤和头皮疾病、浅表伤口、喉咙痛、肥胖和癌症;用于改善肝功能,增强免疫力,促进毛发生长。对荷荷巴油的广泛研究显示出广泛的药理应用,包括抗氧化、抗痤疮和抗牛皮癣、抗炎、抗真菌、解热、镇痛、抗菌和抗高血糖活性。此外,荷荷巴油广泛用于制药行业,特别是用于外用、透皮和非肠道制剂的化妆品中,但目前没有应用于电子烟烟液。
发明内容
本发明的目的是提供一种用荷荷巴油取代或减少丙二醇和甘油作为电子烟烟液的溶剂的应用,荷荷巴油具有承载尼古丁的功能,又能对肺部、支气管和气管细胞进行很好的保护作用,可作为溶剂在制备电子烟烟液中进行应用。
本发明的技术解决方案是,一种荷荷巴油在制备电子烟烟液中的应用,在制备电子烟烟液的过程中,将荷荷巴油作为溶剂使用。
优选地,所述电子烟烟液的组分按重量份包括荷荷巴油5~98份。
优选地,所述电子烟烟液的组分按重量份包括荷荷巴油65~95份。
优选地,所述电子烟烟液的组分按重量份包括荷荷巴油20~60份,丙二醇或甘油或两者的混合物10~35份。
优选地,所述电子烟烟液的组分按重量份还包括柠檬烯1~20份和芳樟醇0.5~10份。
优选地,所述电子烟烟液的组分按重量份还包括乙基香兰素1~10份。
优选地,所述电子烟烟液的组分按重量份还包括烟碱0.5~30份或烟丝提取物1~20份。
优选地,所述电子烟烟液按重量份由以下组分组成:荷荷巴油80~95份、烟碱0.5~30份、柠檬烯2~10份、芳樟醇0.5~5份、叶醇1~2份、肉桂酸甲酯5~10份、乙基香兰素1~5份。
优选地,所述电子烟烟液按重量份由以下组分组成:荷荷巴油70~90份、烟丝提取物3~10份、柠檬烯5~10份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、苯甲酸2.5~5份、乙基香兰素2~5份。
优选地,所述电子烟烟液按重量份由以下组分组成:荷荷巴油65~85份、柠檬烯5~20份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、乙基香兰素1~5份、N,2,3-三甲基-2-异丙基丁酰胺0.5~3份、薄荷油1~2份。
本发明中,荷荷巴油的含量通常可以占电子烟烟液重量份的5~98份,其中,以荷荷巴油取代丙二醇或甘油(丙三醇)、作为唯一溶剂时的含量,荷荷巴油可占电子烟烟液重量份的65~95份。另外,以荷荷巴油为主要溶剂,减少丙二醇或甘油(丙三醇)的含量并将其作为辅助溶剂,以便减轻危害性能的同时改善溶解性能,此时荷荷巴油的含量可占电子烟烟液重量份的20~60份,丙二醇或甘油或两者的混合物减少至10~35份。
本发明通过冷压或溶剂提取种子直接获得的粗荷荷巴油,未经任何修饰,可产生金黄色或浅黄色油。它有一种令人愉快的、略带坚果味的味道。荷荷巴油的热稳定性和氧化稳定性高;因此,由于存在天然抗氧化剂(α、γ和δ生育酚),该油对酸败表现出很高的抵抗力。
本发明中的荷荷巴油毒性研究,有人将粗荷荷巴油喂给小鼠时,未发现急性毒性;即LD50超过160克/公斤。在兔子的眼部刺激试验中,经过除臭或脱臭和变色精制的荷荷巴油在涂油后1小时引起一些可逆的结膜刺激。眼部应用24小时后,逆转作用完全清除。在15天和30天大的豚鼠中,斑贴试验没有引起病理性炎症。局部应用30天后,表皮出现轻度肿胀,较液体石蜡较轻,较橄榄油较明显。然而,对动物皮肤的影响是可逆的,可能是由油膜的封闭性引起的。此外,在大鼠中延长每日皮下注射不会导致血液或尿液分析的任何组织病理学变化。只有注射区域出现轻微的局部可逆肉芽肿反应,表明荷荷巴油具有轻微刺激性。对人类的斑贴试验没有发现过敏反应,除了过敏症患者。对较早接触荷荷巴油两年的人进行的点刺测试显示,对原油或精炼油都没有过敏反应。在Ames试验中,荷荷巴油和氢化荷荷巴蜡的混合物在活化和不活化的情况下都没有致突变性,对皮肤没有刺激作用。
本发明中的荷荷巴油在200~250℃时可以挥发,产生如烟雾状的雾化蒸汽,烟碱,以及含烟碱的烟丝提取物能够很好地与荷荷巴油相溶,烟碱也可以随着荷荷巴油雾化,随烟雾挥发,发挥类似抽烟时烟碱的生理与药理作用。因此,可以采用荷荷巴油代替丙二醇与甘油作为含烟碱的电子烟烟液的溶剂,也可以作为不含烟碱的电子烟烟液的溶剂。
本发明选择荷荷巴油作为电子烟烟液的溶剂,主要基于该油对肺有保护作用,我国科学工作者最近(2021年)在《Pharmaceutics》发表了一篇研究报告,证明了荷荷巴油对肺损伤有很好的保护作用,他们的论文题目是“InhalableJojobaOilDryNanoemulsionPowdersfortheTreatmentofLipopolysacchari de-orH2O2-InducedAcuteLungInjury”(GuoliZhang,Pharmaceutics2021,13,486.),他们用荷荷巴油制备了干纳米乳粉(JNDs)通过动物实验先观察并测量其性质和模拟肺沉积,然后通过动物实验观察其抗急性肺损伤作用。研究者通过给大鼠气管内给予脂多糖(LPS)或过氧化氢(H2O2)后建立大鼠急性肺损伤(ALI)模型。荷荷巴油干纳米乳粉和地塞米松(DXM)溶液也给予大鼠。检查肺组织的病理状态。结果表明荷荷巴油干纳米乳粉对脂多糖诱导的大鼠急性肺损伤的抗炎作用高于地塞米松,总蛋白含量降低,肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和NF-κBp65下调。荷荷巴油干纳米乳粉对H2O2也表现出更高的抗炎和抗氧化作用与地塞米松相比,对脂多糖诱导的大鼠急性肺损伤消除了活性氧(ROS),增加了超氧化物歧化酶(SOD),减少了脂质过氧化物丙二醛(MDA)和谷胱甘肽(GSH),并抑制了caspase-3的表达。此外,它在两种大鼠急性肺损伤模型中减轻了炎症细胞的出血和浸润。荷荷巴油干纳米乳粉是一种很有前途的天然含油可吸入药物,用于治疗LPS或H2O2诱导的大鼠急性肺损伤。因此,可以认为,用荷荷巴油作为电子烟烟液的溶剂是合适的,对急性肺损伤是有保护作用的。因此,荷荷巴油作为电子烟烟液的溶剂,对未来电子烟烟液产品的发展将会引起非常重要的意义。
本发明在荷荷巴油作为电子烟烟液的溶剂中,添加柠檬烯和芳樟醇,可以改善电子烟烟液的口感和风味,特别是没有喉咙干燥的感觉、没有残留物积聚和增加风味强度,同时,也有增加烟碱的增加记忆,改善思维,抗焦虑,抗抑郁的作用。柠檬烯是茜草科的一种单萜,具有抗氧化、抗炎、抗癌、抗伤害和胃保护等生物学特性。近年来,由于柠檬烯能减轻氧化应激和炎症反应,调节细胞凋亡死亡,因此研究其在各种慢性疾病中的药理作用引起了人们的极大兴趣。有文献报告柠檬烯可以与GABA相互作用于A受体,通过增加大脑中的GABA浓度来产生抗焦虑作用。柠檬烯还可通过直接作用于中枢神经系统和嗅觉神经,恢复单胺递质的失衡,发挥改善情绪和抗抑郁作用。芳樟醇也是一种作用于中枢神经系统的单萜烯,它在动物和人类中都显示出了抗惊厥和镇静的作用,芳樟醇的作用与5-羟色胺能通路有关,通过与柠檬烯不同的途径调控脑组织的单胺递质,而产生抗抑郁的作用,研究认为芳樟醇的抗抑郁样作用是通过突触后5-HT与5-羟色胺能通路相互作用而发挥作用的,此外,还与肾上腺素能系统的α受体和多巴胺能系统的D1受体作用有相互关系。
本发明在荷荷巴油溶剂中添加柠檬烯和芳樟醇,可以加强电子烟烟液中烟碱的有益的作用,同时在药剂学方面还可使烟碱的分布更加均匀,电子雾化更加彻底,碳化残留量极微,而且口感及风味更好,是荷荷巴油配制电子烟烟液的最佳伴侣。
本发明荷荷巴油溶剂中添加了柠檬烯和芳樟醇之后,再添加,叶醇,薄荷醇,香兰素,乙基香兰素,N,2,3-三甲基-2-异丙基丁酰胺等物质后,可以不添加烟碱,我们也可得到的风味口感与含有烟碱的电子烟烟液相似产品,我们把这种产品称为“不含尼古丁的电子戒烟液”,该电子戒烟液不含烟碱,但又具有烟碱的抑制单胺氧化酶,促进乙酰胆碱,5-羟色胺和多巴胺等单胺类神经递质发挥有益的生理功能,改善思维,稳定情绪及预防抑郁症状等作用。
本发明应用荷荷巴油作为溶剂制备的电子烟烟液,经药剂学检测,符合电子烟烟液的质量要求,经动物实验观察,小白鼠连续吸本发明的电子烟烟液2个月,每天两次,每次1小时,没有发现毒性反应,对心脏、肺脏及脑组织的病理检查,没有发现有病理形态学的改变。研究表明,本发明技术方案配制的电子烟烟液对小白鼠连续吸烟2个月不会引起毒性。
综上,与现有技术相比,本发明的有益效果是:
本发明应用荷荷巴油作为溶剂制备电子烟烟液,解决了以丙二醇和甘油作为溶剂存在的缺陷,特别是长期应用可能对使用者造成不利的影响,本发明提出的用于取代或减少丙二醇和甘油作为电子烟烟液溶剂的荷荷巴油,没有毒性,具有运载与雾化尼古丁的功能,又能对肺部,支气管和气管细胞有很好的保护作用,对皮肤没有刺激作用,对酸败表现出很高的抵抗力。另外,本发明在荷荷巴油作为电子烟烟液的溶剂中,添加柠檬烯和芳樟醇,可以改善电子烟烟液的口感和风味,特别是没有喉咙干燥的感觉、没有残留物积聚和增加风味强度,同时,也有增加烟碱的增加记忆,改善思维,抗焦虑,抗抑郁的作用。
具体实施方式
本发明下面将结合实施例作进一步详述:
本发明阐述的是一种荷荷巴油在制备电子烟烟液中的应用,即在制备电子烟烟液的过程中,将荷荷巴油作为溶剂使用。
本发明的一个实施方案是,电子烟烟液的组分按重量份包括用作溶剂的荷荷巴油5~98份,其它组分包括柠檬烯1~20份、芳樟醇0.5~10份、乙基香兰素1~10份、烟碱0.5~30份或烟丝提取物1~20份。其中,更加具体地,荷荷巴油可以在51~59份、或61~69份、或71~79份、或81~85份、或86~90份、或91~98份之中选配;烟碱可在0.5~5份、或6~10份、或11~20份、或21~30份之中选配;烟丝提取物可以在1~10份、或11~20份之间选配;柠檬烯可以在1~5份、或6~9份,或11~20份之间选配;芳樟醇可以在0.6~3份、或3~6份、或7~9份之间选配;乙基香兰素可以在1~4份、或5~7份、或8~10份之间选配。
本发明的另一个实施方案是,电子烟烟液的组分按重量份包括用作溶剂的荷荷巴油20~60份、丙二醇或甘油或丙二醇与甘油的混合物10~35份、其它组分包括柠檬烯1~20份、芳樟醇0.5~10份、乙基香兰素1~10份、烟碱0.5~30份或烟丝提取物1~20份。其中,更加具体地,荷荷巴油可以在21~29份、或31~39份、或41~49份、或51~59份之中选配;烟碱可在0.5~5份、或6~10份、或11-20份、或21-30份之中选配;烟丝提取物可以在1~10份、或11~20份之间选配;柠檬烯可以在1~5份、或6~9份,或11~20份之间选配;芳樟醇可以在0.6~3份、或3~6份、或7~9份之间选配;乙基香兰素可以在1~4份、或5~7份、或8~10份之间选配。
本发明的又一个实施方案是,电子烟烟液按重量份由以下组分组成:作为溶剂的荷荷巴油80~95份,其它组分包括烟碱0.5~30份、柠檬烯2~10份、芳樟醇0.5~5份、叶醇1~2份、肉桂酸甲酯5~10份、乙基香兰素1~5份。
本发明的又一个实施方案是,电子烟烟液按重量份由以下组分组成:作为溶剂的荷荷巴油70~90份、其它组分包括烟丝提取物3~10份、柠檬烯5~10份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、苯甲酸2.5~5份、乙基香兰素2~5份。
本发明的再一个实施方案是,电子烟烟液按重量份由以下组分组成:作为溶剂的荷荷巴油65~85份、其它组分包括柠檬烯5~20份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、乙基香兰素1~5份、N,2,3-三甲基-2-异丙基丁酰胺0.5~3份、薄荷油1~2份。
本发明具体的实施例如下:
实施例一
以荷荷巴油为溶剂并含有烟碱的的电子烟烟液的配方及制备方法是:取80.5g荷荷巴油,然后在该荷荷巴油中添加烟碱1.5g、柠檬烯5g、芳樟醇5g、叶醇1g、肉桂酸甲酯5g、乙基香兰素2g,适当加温充分溶解即得。
实施例二
以荷荷巴油为溶剂并含有烟碱的的电子烟烟液的配方及制备方法是:取50g荷荷巴油,然后在该荷荷巴油中添加丙三醇25g、烟碱1.5g、柠檬烯8g、芳樟醇5g、叶醇1.5g、肉桂酸甲酯7g、乙基香兰素2g,适当加温充分溶解即得。
本实施例中,以荷荷巴油为主要溶剂成分,添加丙三醇作为辅助溶剂成分。
实施例三
以荷荷巴油为溶剂并含有烟碱的电子烟烟液的另一配方及制备方法是:取78g的荷荷巴油,然后在该荷荷巴油中添加烟碱1.5g、柠檬烯5g、芳樟醇5g、叶醇1g、肉桂酸甲酯5g、苯甲酸2.5g、乙基香兰素2g,适当加温充分溶解即得。
实施例四
以荷荷巴油为溶剂并含有烟丝提取物的电子烟烟液的配方及制备方法是:取荷荷巴油75g,然后在该荷荷巴油中添加烟丝提取物10g、柠檬烯5g、芳樟醇2g、叶醇1g、肉桂酸甲酯5g、乙基香兰素2g,适当加温充分溶解即得。
实施例五
以荷荷巴油为溶剂且不含烟碱的的电子烟烟液的另一配方及制备方法是:取荷荷巴油80g、然后在该荷荷巴油中分别添加柠檬烯8g、芳樟醇1.5g、叶醇1g、肉桂酸甲酯5g、乙基香兰素1.5g、N,2,3-三甲基-2-异丙基丁酰胺1g、薄荷油2g,适当加温充分溶解即可。
本发明以上实施方案和实施例中,以荷荷巴油为溶剂的电子烟烟液溶液中,添加了有关成分如:芳樟醇、柠檬烯、叶醇、薄荷醇、香兰素、乙基香兰素、N,2,3-三甲基-2-异丙基丁酰胺、苯甲酸及国家电子烟标准中允许添加其他的物质,以改善电子烟烟液的口感和风味。
本发明按实施例的技术方案配制的电子烟烟液,经药剂学检测,符合电子烟烟液的质量要求,经动物实验观察,小白鼠连续吸本发明的电子烟烟液2个月,每天两次,每次1小时,没有发现毒性反应,对心脏、肺脏及脑组织的病理检查,没有发现有病理形态学的改变。研究表明,本发明技术方案配制的电子烟烟液对小白鼠连续吸烟2个月不会引起毒性。
以上所述仅为本发明的较佳实施例,凡依本发明权利要求范围所做的均等变化与修饰,皆应属本发明权利要求的涵盖范围。
Claims (10)
1.一种荷荷巴油在制备电子烟烟液中的应用,其特征在于,在制备电子烟烟液的过程中,将荷荷巴油作为溶剂使用。
2.根据权利要求1所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份包括荷荷巴油5~98份。
3.根据权利要求1所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份包括荷荷巴油65~95份。
4.根据权利要求1所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份包括荷荷巴油20~60份,丙二醇或甘油或两者的混合物10~35份。
5.根据权利要求2-4任一项所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份还包括柠檬烯1~20份和芳樟醇0.5~10份。
6.根据权利要求2-4任一项所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份还包括乙基香兰素1~10份。
7.根据权利要求2-4任一项所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液的组分按重量份还包括烟碱0.5~30份或烟丝提取物1~20份。
8.根据权利要求2所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液按重量份由以下组分组成:荷荷巴油80~95份、烟碱0.5~30份、柠檬烯2~10份、芳樟醇0.5~5份、叶醇1~2份、肉桂酸甲酯5~10份、乙基香兰素1~5份。
9.根据权利要求2所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液按重量份由以下组分组成:荷荷巴油70~90份、烟丝提取物3~10份、柠檬烯5~10份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、苯甲酸2.5~5份、乙基香兰素2~5份。
10.根据权利要求2所述荷荷巴油在制备电子烟烟液中的应用,其特征在于,所述电子烟烟液按重量份由以下组分组成:荷荷巴油65~85份、柠檬烯5~20份、芳樟醇1~5份、叶醇1~3份、肉桂酸甲酯5~10份、乙基香兰素1~5份、N,2,3-三甲基-2-异丙基丁酰胺0.5~3份、薄荷油1~2份。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211232830.8A CN115736319A (zh) | 2022-10-10 | 2022-10-10 | 荷荷巴油在制备电子烟烟液中的应用 |
PCT/CN2023/123137 WO2024078373A1 (zh) | 2022-10-10 | 2023-10-07 | 荷荷巴油在制备电子烟烟液中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211232830.8A CN115736319A (zh) | 2022-10-10 | 2022-10-10 | 荷荷巴油在制备电子烟烟液中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115736319A true CN115736319A (zh) | 2023-03-07 |
Family
ID=85350980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211232830.8A Pending CN115736319A (zh) | 2022-10-10 | 2022-10-10 | 荷荷巴油在制备电子烟烟液中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115736319A (zh) |
WO (1) | WO2024078373A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024078373A1 (zh) * | 2022-10-10 | 2024-04-18 | 惠州市新泓威科技有限公司 | 荷荷巴油在制备电子烟烟液中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101264277B (zh) * | 2008-04-16 | 2012-09-26 | 冯冲 | 一种控烟戒烟复方精油 |
CN104905400B (zh) * | 2015-04-29 | 2016-08-03 | 昆明理工大学 | 一种烟草保润剂及其制备方法 |
EP3614869A1 (en) * | 2017-04-24 | 2020-03-04 | Swedish Match North Europe AB | A flavoured moist oral pouched nicotine product comprising triglyceride |
CN110506981A (zh) * | 2019-09-12 | 2019-11-29 | 深圳雾芯科技有限公司 | 风味组合物及包含所述风味组合物的电子烟液 |
CN113558278A (zh) * | 2021-08-23 | 2021-10-29 | 深圳芳芯科技有限公司 | 风味组合物及包含所述风味组合物的电子烟液 |
CN115736319A (zh) * | 2022-10-10 | 2023-03-07 | 惠州市新泓威科技有限公司 | 荷荷巴油在制备电子烟烟液中的应用 |
-
2022
- 2022-10-10 CN CN202211232830.8A patent/CN115736319A/zh active Pending
-
2023
- 2023-10-07 WO PCT/CN2023/123137 patent/WO2024078373A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024078373A1 (zh) * | 2022-10-10 | 2024-04-18 | 惠州市新泓威科技有限公司 | 荷荷巴油在制备电子烟烟液中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2024078373A1 (zh) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Whittle et al. | Prospects for new cannabis-based prescription medicines | |
US20050042172A1 (en) | Administration of medicaments by vaporisation | |
Remberg et al. | Characteristics, clinical effect profile and tolerability of a nasal spray preparation of Artemisia abrotanum L. for allergic rhinitis | |
WO2024078373A1 (zh) | 荷荷巴油在制备电子烟烟液中的应用 | |
KR20190026692A (ko) | 신규한 흰무늬엉겅퀴 수과 추출물 및 피부과 및 피부 화장료에서 이의 용도 | |
KR102055499B1 (ko) | 감국꽃 정유를 유효성분으로 포함하는 뇌파에서 상대적 세타파는 감소시키고 상대적 알파파는 증가시키는 향료 조성물 및 이의 용도 | |
EP2152227A1 (en) | A liquid formulation for administering nicotine | |
CN103750539B (zh) | 一种消炎抗菌型烟草鼻腔喷剂组合物及其制备方法 | |
CN113662234A (zh) | 抑菌抗菌的雾化液及其制备方法 | |
Stępniowska et al. | Selected Alkaloids Used in the Cosmetics Industry. | |
CN109998151B (zh) | 中链甘油三酯在改善和/或减少呼吸道刺激中的应用 | |
CN114732151A (zh) | 一种有助于缓解疲劳的电子烟烟油及其加工方法 | |
US11957786B2 (en) | Liquid vape base and extraction process | |
JP5302526B2 (ja) | ヨモギ精油外用剤 | |
CN108703899B (zh) | 护肤按摩精油 | |
CN112656716A (zh) | 一种绿色健康护肤霜及其制备方法 | |
JP2018503671A (ja) | アステリスクスグラベオレンス抽出物及びその使用 | |
KR20200116094A (ko) | 오염과 관련된 손상의 치료 및 예방을 위한 토목향(Inula helenium) 추출물 | |
CN110373264A (zh) | 一种用于烟草制品的含有工业大麻精油的组合物 | |
JP6590233B1 (ja) | 皮膚疾患治療剤及びその製造方法 | |
Mondal | Psidiumguajava (Guava) Leaves as a Potential Treatment of Scurvy | |
US7687081B2 (en) | Herbal formulation useful as local anesthetic | |
Guy et al. | Prospects for New Cannabis-Based Prescription Medicines: Brian A. Whittle, Geoffrey W. Guy, Philip Robson | |
CN103767062B (zh) | 一种抗晕止吐型烟草凝胶剂及其制备方法 | |
TW200416000A (en) | Cigarette capable of assisting a smoker to quit smoking and the method for producing such a cigarette |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |